Vessel vs ArkeaBio

Side-by-side comparison of AI visibility scores, market position, and capabilities

Vessel

EmergingDeveloper Tools

Go-to-Market Integration APIs

Vessel provides unified CRM and sales tool APIs enabling B2B SaaS products to natively integrate with Salesforce, HubSpot, and other go-to-market platforms.

About

Vessel is a developer tools company founded in 2022 that provides unified APIs for CRM and sales technology integrations, allowing B2B SaaS products to connect with customers' Salesforce, HubSpot, Pipedrive, and other GTM tools through a single normalized API. The company targets revenue intelligence, sales engagement, and analytics tools whose primary value depends on seamless data access to and from customer CRM systems. Building and maintaining native CRM integrations is notoriously complex given the depth of Salesforce and HubSpot's data models, authentication complexity, and rate limiting requirements. Vessel abstracts these complexities into a unified data model and connection management platform that reduces integration development time from months to days. The company raised $5M and serves B2B SaaS companies whose products are embedded in the sales and marketing tech stack. Vessel handles OAuth connection management, data normalization across CRM schemas, webhook forwarding, and write-back operations, providing a complete bidirectional integration layer. The platform is particularly valuable for startups in the GTM tech space that need CRM integrations to close enterprise deals but lack the engineering capacity to build and maintain them in-house.

Full profile

ArkeaBio

EmergingAgTech

Livestock Biotech (Methane Reduction)

$40M+ total raised including $26.5M Series A. 2026-27 cattle field trials underway. Backed by Breakthrough Energy Ventures. Only company with a cattle methane vaccine in active trials.

About

ArkeaBio is developing a vaccine that reduces methane emissions from cattle and sheep by targeting the methanogenic archaea (ancient microorganisms) that produce methane in ruminant digestive systems. The company has raised $40 million+ including a $26.5 million Series A, backed by Breakthrough Energy Ventures and Gates Foundation-aligned capital, and has active cattle field trials underway in 2026-2027 — making it the only company with a livestock methane vaccine at this stage of clinical development.

Full profile

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.